Polycystic Kidney Disease (PKD): Complete Guide for Patients in Punjab

What is Polycystic Kidney Disease (PKD)?

Polycystic kidney disease (PKD) is a genetic disorder in which numerous fluid-filled cysts (like small balloons filled with fluid) develop within the kidneys. Over time, these cysts grow in number and size, gradually replacing normal kidney tissue and reducing kidney function. PKD is the most common life-threatening genetic disease globally, affecting approximately 1 in 400–1000 people — meaning that in Punjab alone, hundreds of thousands of people may be affected.

The most common form is Autosomal Dominant PKD (ADPKD), which means a child of an affected parent has a 50% chance of inheriting the condition. Symptoms typically appear in adulthood (30s-40s) but cysts begin forming from childhood or even before birth. ADPKD accounts for 5-10% of all patients requiring dialysis worldwide. With proactive management under Dr. Swaranjeet Kaur's care in Bathinda, many PKD patients can preserve their kidney function significantly beyond average expectations.

Types of Polycystic Kidney Disease

1. Autosomal Dominant PKD (ADPKD) — Most Common Form

Caused by mutations in PKD1 (chromosome 16, more severe) or PKD2 (chromosome 4, milder) genes. Just one copy of the mutated gene from either parent causes the disease. Most patients develop kidney failure between 50-70 years of age (PKD1) or later (PKD2), though significant variation exists. Affects approximately 1 in 500-1000 people.

2. Autosomal Recessive PKD (ARPKD) — Childhood Form

Rare (1 in 20,000 births). Both parents must carry the mutated gene. Presents in infancy or childhood with larger kidneys, liver fibrosis, and often severe early kidney disease. Managed by pediatric nephrologists.

Symptoms of Polycystic Kidney Disease (ADPKD)

ADPKD progresses silently for many years. Symptoms typically begin between age 30-50:

• Hypertension (High Blood Pressure) — Often the first manifestation, appearing in the 20s-30s. May be severe and require multiple medicines. Caused by cyst-related activation of the renin-angiotensin system.
• Flank or abdominal pain — Dull aching pain or heaviness in the back or sides from enlarged kidneys, cyst complications (bleeding into cyst, rupture, infection)
• Blood in urine (haematuria) — Can be gross (visible) or microscopic. Episodes may last 2-7 days.
• Abdominal fullness and early satiety — Massively enlarged kidneys can compress the stomach and other organs
• Urinary tract infections and kidney infections — Cysts are prone to infection; infected cysts are difficult to treat and can recur
• Kidney stones — More common in PKD than in general population
• Symptoms of declining kidney function — Fatigue, swelling, breathlessness as CKD progresses

Extra-Kidney (Extrarenal) Manifestations of ADPKD

PKD affects not just the kidneys but multiple organ systems:

• Liver cysts — Present in up to 80% of ADPKD patients. Usually asymptomatic but can become large, causing abdominal discomfort or compression
• Intracranial aneurysms — Approximately 5-10% of ADPKD patients have brain aneurysms that can rupture, causing life-threatening brain hemorrhage. Family history of rupture increases risk significantly
• Heart valve abnormalities — Mitral valve prolapse in 25% of patients
• Hernia — Abdominal hernias more common
• Diverticular disease — Colon diverticula

How PKD is Diagnosed

• Kidney ultrasound — First-line investigation. Multiple cysts in both kidneys in a patient with family history is highly diagnostic. Diagnostic criteria: age-specific number of cysts required for diagnosis
• MRI scan — More sensitive than ultrasound; used for monitoring Total Kidney Volume (TKV) which predicts disease progression rate
• CT scan — Shows cyst details but involves radiation
• Genetic testing — Can identify PKD1 or PKD2 mutations; useful in atypical cases or for family screening and pre-implantation genetic diagnosis for family planning

Management of PKD at Pragma Medical Institute, Bathinda

1. Blood Pressure Control — Most Critical Intervention

Strict BP control (below 130/80 mmHg, or even lower in young patients) is the single most important modifiable factor in slowing PKD progression. ACE inhibitors or ARBs are first-line. Achieving this early in the disease course can preserve kidney function for many additional years.

2. Tolvaptan — Disease-Modifying Treatment

Tolvaptan (a vasopressin V2 receptor antagonist) is approved for rapidly progressive ADPKD in adults. It reduces cyst growth rate and slows kidney function decline by approximately 35% compared to placebo. Dr. Swaranjeet Kaur evaluates eligible PKD patients for tolvaptan therapy with careful monitoring (regular liver function tests required).

3. Managing Complications

• Cyst infections: prolonged antibiotic courses (fluoroquinolones penetrate cysts best)
• Cyst bleeding: bed rest, hydration, pain control (usually resolves in 2-7 days)
• Kidney stones: hydration, dietary advice, specific medicines
• Intracranial aneurysm screening: MRI brain angiography for high-risk patients (family history of rupture)

4. Dialysis and Transplant Planning

As PKD progresses to CKD Stages 4-5, Dr. Swaranjeet Kaur initiates early planning for kidney replacement therapy. Transplant is excellent for PKD patients — the condition does not recur in the transplanted kidney. PKD patients can also be living donors for family members, though genetic counselling is important.

5. Lifestyle Recommendations

• High water intake (2.5-3 litres/day) — suppresses vasopressin and reduces cyst growth if tolerated
• Caffeine restriction — caffeine promotes cyst growth
• Low-sodium diet
• Avoid contact sports that risk flank injury
• Regular moderate exercise
• No smoking